<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877992</url>
  </required_header>
  <id_info>
    <org_study_id>IVISEVILLA</org_study_id>
    <nct_id>NCT02877992</nct_id>
  </id_info>
  <brief_title>Tachykinin and Kisspeptin Expression in Human Granulosa and Cumulus Cells</brief_title>
  <official_title>Development of a New Diagnostic Tool to Assess Oocyte Quality Based on Tachykinin and Kisspeptin Expression Analysis in Human Granulosa and Cumulus Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Sevilla</source>
  <brief_summary>
    <textblock>
      The purpose of this project is to study the presence of expression differences - at RNA and
      protein level - of different members of the tachykinin family and kisspeptin and their
      receptors, between fertile women and infertile patients with different etiologies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expression level of Substance P (SP)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA (mRNA = messenger ribonucleic acid) and protein level using techniques of real time quantitative PCR (PCR = polymerase chain reaction), immunocytochemistry and western blot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of neurokinin A (NKA)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of neurokinin B (NKB)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of hemokinin 1 (HK-1)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of neurokinin 1 receptor (NK1R)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression of neurokinin 2 receptor (NK2R)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of neurokinin 3 receptor (NK3R)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of kisspeptin 1 (KISS1)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of kisspeptin 1 receptor (KISS1R)</measure>
    <time_frame>4 years</time_frame>
    <description>Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient or donor age</measure>
    <time_frame>4 years</time_frame>
    <description>Years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient or donor body mass index</measure>
    <time_frame>4 years</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Years of infertility</measure>
    <time_frame>4 years</time_frame>
    <description>Number of years that the patient has been trying to have a child without success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol level (day of ovulation induction)</measure>
    <time_frame>4 years</time_frame>
    <description>Estradiol level in blood (pg/mL), measured the day in which ovulation is induced</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesterone level (day of ovulation induction)</measure>
    <time_frame>4 years</time_frame>
    <description>Progesterone level in blood (ng/mL), measured the day in which ovulation is induced</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved in the ovarian puncture</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mature oocytes (metaphase II) obtained in the ovarian puncture</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>4 years</time_frame>
    <description>Proportion of oocytes correctly fertilized (2 pronuclei and 2 polar bodies) after the ICSI (ICSI = intracytoplasmic sperm injection) procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality</measure>
    <time_frame>4 years</time_frame>
    <description>Embryo quality at day 3 of embryo development (of each embryo of the cohort). Quality assessed according to ASEBIR (ASEBIR = &quot;Asociación Española para el estudio de la Biología de la Reproducción&quot; = Spanish society for reproductive biology) criteria. Embryo quality grade A to D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily and total dose of FSH (FSH = follicle stimulating hormone)</measure>
    <time_frame>4 years</time_frame>
    <description>Daily dose of FSH for controlled ovarian stimulation. International Units (IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily and total dose of HMG (HMG = human menopausal gonadotropin)</measure>
    <time_frame>4 years</time_frame>
    <description>Daily dose of HMG for controlled ovarian stimulation. International Units (IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of ovulation induction</measure>
    <time_frame>4 years</time_frame>
    <description>Ovulation induction using 6500 IU of hCG (hCG = human chorionic gonadotropin) or 0.2 mg of triptorelin (Decapeptyl)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Donors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oocyte donors without infertility problems</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometriosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with endometriosis (I-IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced maternal age (38 years or more)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low ovarian response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with low ovarian response according to Bologna criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ovarian puncture</intervention_name>
    <description>Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.</description>
    <arm_group_label>Donors</arm_group_label>
    <arm_group_label>PCOS</arm_group_label>
    <arm_group_label>Endometriosis</arm_group_label>
    <arm_group_label>Age</arm_group_label>
    <arm_group_label>Low ovarian response</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Two groups of subjects (each one with different criteria):

          1. Oocyte donors

             Inclusion Criteria:

               -  Age between 18 and 34 years

               -  Normal caryotype

               -  Normal psychological test

             Exclusion Criteria:

               -  Presence of hereditary diseases

               -  Beta-thalassemia

               -  Cystic fibrosis

               -  Human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus
                  (HCV)

          2. Infertility patients

        Inclusion Criteria:

          -  Age between 18 and 45 years

          -  One of the following etiologies:

          -  Patient with PCOS according to Rotterdam Criteria or

          -  Patients with endometriosis stage I-IV or

          -  Patients with low ovarian response according to Bologna criteria or

          -  Patients with advances maternal age (between 38 and 45 years)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Víctor Blasco, MSc</last_name>
    <phone>+34 954 286 274</phone>
    <phone_ext>19523</phone_ext>
    <email>victor.blasco@ivi.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto de Investigaciones Químicas</name>
      <address>
        <city>Sevilla</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luz Candenas, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IVI Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Víctor Blasco, MSc</last_name>
      <phone>+34 954 286 274</phone>
      <phone_ext>19523</phone_ext>
      <email>victor.blasco@ivi.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>García-Ortega J, Pinto FM, Fernández-Sánchez M, Prados N, Cejudo-Román A, Almeida TA, Hernández M, Romero M, Tena-Sempere M, Candenas L. Expression of neurokinin B/NK3 receptor and kisspeptin/KISS1 receptor in human granulosa cells. Hum Reprod. 2014 Dec;29(12):2736-46. doi: 10.1093/humrep/deu247. Epub 2014 Oct 14.</citation>
    <PMID>25316443</PMID>
  </reference>
  <results_reference>
    <citation>García-Ortega J, Pinto FM, Prados N, Bello AR, Almeida TA, Fernández-Sánchez M, Candenas L. Expression of Tachykinins and Tachykinin Receptors and Interaction with Kisspeptin in Human Granulosa and Cumulus Cells. Biol Reprod. 2016 Jun;94(6):124. doi: 10.1095/biolreprod.116.139881. Epub 2016 May 4.</citation>
    <PMID>27146034</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Sevilla</investigator_affiliation>
    <investigator_full_name>Manuel Fernandez-Sanchez</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>Tachykinin</keyword>
  <keyword>Kisspeptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachykinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

